Ichnos Glenmark Innovation (IGI), a clinical-stage biotech company specializing in oncology, has appointed Dr. Mariana Cota Stirner as its new Chief Medical Officer. Dr. Cota Stirner brings over 20 years of experience in oncology and hematology drug development, having held key roles at companies like AbbVie, Bristol Myers Squibb, and Novartis. Her leadership is expected to advance IGI's innovative Multispecific™ antibody pipeline, including their first-in-class immune cells activator, aiming to develop new treatments for difficult cancers. This strategic hire underscores IGI's commitment to pioneering next-generation cancer therapies using its proprietary BEAT® platform.
Barclays increased its price target for Hudbay Minerals to $32 from $30, citing strong growth prospects in copper mining. Despite a recent nearly 30% stock pullback due to market sentiment, Hudbay maintains a solid financial position with near-zero n...
Morgan Stanley reported strong Q2 2026 results, with earnings per share of $3.46 surpassing estimates of $2.89 and revenue of $21.35 billion beating forecasts of $19.67 billion. This marks significant year-over-year growth from $16.79 billion, driven...
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
